Form 4: Eli Lilly Director Defers Stock Compensation

Eli Lilly Director J. Erik Fyrwald acquired 13.254 shares of common stock, deferring them as stock units under the company's deferral plan.

Summary

• J. Erik Fyrwald, a Director at Eli Lilly & Co (LLY), acquired 13.254 shares of common stock.
• The transaction occurred on September 15, 2025, with a price of $748.19 per share.
• The acquired shares were deferred as stock units under the Lilly Directors' Deferral Plan.
• These stock units will be settled in shares of common stock following Mr. Fyrwald's separation from service.
• Following this transaction, Mr. Fyrwald beneficially owns a total of 74,751.392 shares of common stock.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event where a director increases their beneficial ownership through a compensation deferral plan, aligning their interests with shareholders. It does not suggest any negative operational or financial issues.

Positives

• The acquisition of additional shares by a director, even through deferred compensation, indicates continued alignment of management interests with shareholder value.
• The deferral plan allows directors to increase their stake in the company without immediate tax implications, potentially encouraging long-term commitment.

Future Outlook

The acquired stock units will be settled in shares of common stock following the reporting person's separation from service, indicating a future distribution event tied to the director's tenure.

Industry Context

It is a common practice in the pharmaceutical and broader corporate sectors for directors to receive a portion of their compensation in company stock or stock units, often with deferral options, to align their long-term interests with those of shareholders.

Comparison to Industry Standards

• Stock-based compensation and deferral plans for directors are standard practice across major U.S. public companies, including those in the pharmaceutical industry.
• The structure of deferring stock units until separation from service is a common mechanism to encourage long-term commitment and align director incentives with sustained company performance, similar to practices at peer companies like Pfizer, Merck, or Johnson & Johnson.

Corporate Governance

Related Party Transactions

• The acquisition of common stock by J. Erik Fyrwald, a Director of Eli Lilly & Co, through the Lilly Directors' Deferral Plan, constitutes a related party transaction as it involves a company insider and the issuer.

Stakeholder Impact

• Shareholders: The transaction aligns the director's financial interests more closely with those of shareholders by increasing their beneficial ownership in the company.
• Employees: No direct impact mentioned.

Next Steps

• Settlement of the deferred stock units into common stock upon J. Erik Fyrwald's separation from service.

Key Dates

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Director Compensation, Stock Units, Deferred Compensation, J. Erik Fyrwald